drugset / Trial / NCT05587283

Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women

NCT05587283 ↗

RandomizedParallel-groupQuadruple-blindOther

Summary

This is a phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled, dose escalation, clinical trial enrolling 24 healthy participants. The main subject is to investigate the safety and tolerability of the LABTHERA-001 capsule and to explore the acceptability of the capsule.

Timeline

Start
2022-11-02
Primary completion
2023-04
Completion
2023-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject LABTHERA-001 Other / unclassified 2e+08 cells Other
Subject LABTHERA-001 Other / unclassified 1e+09 cells Other
Subject LABTHERA-001 Other / unclassified 5e+09 cells Other

Indications